Q2 2017 13F Holders as of 6/30/2017
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
123M
-
Number of holders
-
67
-
Total 13F shares, excl. options
-
33.9M
-
Shares change
-
+8.7M
-
Total reported value, excl. options
-
$93.7M
-
Value change
-
+$24.7M
-
Put/Call ratio
-
0.04
-
Number of buys
-
43
-
Number of sells
-
-18
-
Price
-
$2.76
Significant Holders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) as of Q2 2017
79 filings reported holding CPRX - CATALYST PHARMACEUTICALS, INC. - COMMON STOCK as of Q2 2017.
CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) has 67 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 33.9M shares
of 123M outstanding shares and own 27.56% of the company stock.
Largest 10 shareholders include Broadfin Capital, LLC (7.35M shares), BAKER BROS. ADVISORS LP (5.1M shares), venBio Select Advisor LLC (3.8M shares), BlackRock Inc. (3.59M shares), VANGUARD GROUP INC (3.35M shares), JPMORGAN CHASE & CO (1.54M shares), STATE STREET CORP (938K shares), KENNEDY CAPITAL MANAGEMENT, INC. (918K shares), RENAISSANCE TECHNOLOGIES LLC (892K shares), and NORTHERN TRUST CORP (803K shares).
This table shows the top 67 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.